Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients
- PMID: 1628369
- DOI: 10.1007/BF00686313
Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients
Abstract
The pharmacokinetics and metabolism of cyclophosphamide were studied in nine paediatric patients. Plasma samples were obtained from eight subjects and urine was collected from six children during a 24-h period after drug administration. Cyclophosphamide and its major metabolites phosphoramide mustard (PM), carboxyphosphamide (CX), dechloroethylcyclophosphamide (DCCP) and 4-ketocyclophosphamide (KETO) were determined in plasma and urine using high-performance thin-layer chromatography-photographic densitometry (HPTLC-PD). Cyclophosphamide (CP) was nearly, if not completely, cleared from plasma by 24 h after its administration. The plasma half-life of CP ranged from 2.15 to 8.15 h; it decreased following higher doses and was shorter than that previously reported for adult patients. Both the apparent volume of distribution (0.49 +/- 1.4 l/kg) and the total body clearance (2.14 +/- 1.4 l m-2 h-1) increased with increasing dose. Renal clearance ranged between 0.12 and 0.58 l/h (mean, 0.43 +/- 0.19 l/h). Between 5.4% and 86.1% of the total delivered dose was recovered as unchanged drug in the urine. The major metabolites identified in plasma and urine were PM and CX. One patient appeared to be deficient in CX formation. This study suggests that there is interpatient variability in the pharmacokinetics and metabolism of CP in paediatric patients. The shorter half-life and higher clearance as compared with adult values indicate faster CP metabolism in children.
Similar articles
-
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.Ther Drug Monit. 2005 Dec;27(6):756-65. doi: 10.1097/01.ftd.0000177224.19294.92. Ther Drug Monit. 2005. PMID: 16306851 Clinical Trial.
-
Cyclophosphamide metabolism in children.Cancer Res. 1995 Feb 15;55(4):803-9. Cancer Res. 1995. PMID: 7850793
-
Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion.Cancer Chemother Pharmacol. 2001 Mar;47(3):222-8. doi: 10.1007/s002800000220. Cancer Chemother Pharmacol. 2001. PMID: 11320665
-
Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet. 1991 Mar;20(3):194-208. doi: 10.2165/00003088-199120030-00002. Clin Pharmacokinet. 1991. PMID: 2025981 Review.
-
The analysis of cyclophosphamide and its metabolites.Curr Pharm Des. 1999 Aug;5(8):561-86. Curr Pharm Des. 1999. PMID: 10469892 Review.
Cited by
-
Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group.J Clin Pharmacol. 2009 Jan;49(1):88-102. doi: 10.1177/0091270008325928. Epub 2008 Oct 16. J Clin Pharmacol. 2009. PMID: 18927240 Free PMC article.
-
Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma.Sci Rep. 2023 Jul 21;13(1):11770. doi: 10.1038/s41598-023-38983-0. Sci Rep. 2023. PMID: 37479763 Free PMC article.
-
Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis.Sci Rep. 2018 Jan 29;8(1):1773. doi: 10.1038/s41598-018-19761-9. Sci Rep. 2018. PMID: 29379115 Free PMC article.
-
Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003. Clin Pharmacokinet. 2005. PMID: 16231966 Review.
-
Optimizing Rhabdomyosarcoma Treatment in Adolescents and Young Adults.Cancers (Basel). 2022 May 2;14(9):2270. doi: 10.3390/cancers14092270. Cancers (Basel). 2022. PMID: 35565399 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous